Equities analysts expect Coherus Biosciences Inc (NASDAQ:CHRS) to report sales of $100.33 million for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Coherus Biosciences’ earnings, with the highest sales estimate coming in at $103.73 million and the lowest estimate coming in at $98.30 million. Coherus Biosciences reported sales of $83.43 million in the same quarter last year, which would indicate a positive year over year growth rate of 20.3%. The company is expected to report its next earnings results on Thursday, August 6th.
On average, analysts expect that Coherus Biosciences will report full year sales of $440.35 million for the current fiscal year, with estimates ranging from $423.00 million to $460.00 million. For the next fiscal year, analysts forecast that the company will post sales of $448.78 million, with estimates ranging from $410.60 million to $495.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Coherus Biosciences.
Coherus Biosciences (NASDAQ:CHRS) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.10. The company had revenue of $116.18 million during the quarter, compared to analysts’ expectations of $116.25 million. Coherus Biosciences had a net margin of 33.42% and a return on equity of 190.82%.
CHRS opened at $17.42 on Wednesday. The company’s 50-day moving average price is $17.77 and its 200 day moving average price is $17.75. Coherus Biosciences has a fifty-two week low of $10.86 and a fifty-two week high of $23.91. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of 8.89 and a beta of 2.10. The company has a quick ratio of 3.18, a current ratio of 3.32 and a debt-to-equity ratio of 1.21.
In other Coherus Biosciences news, COO Vincent R. Anicetti sold 2,500 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $17.22, for a total value of $43,050.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Mary T. Szela sold 54,997 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $17.58, for a total transaction of $966,847.26. Following the completion of the sale, the director now owns 14,997 shares in the company, valued at $263,647.26. The disclosure for this sale can be found here. Insiders sold a total of 268,925 shares of company stock worth $4,627,867 over the last quarter. 15.86% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of CHRS. Alliancebernstein L.P. boosted its position in shares of Coherus Biosciences by 293.0% during the 4th quarter. Alliancebernstein L.P. now owns 2,178,030 shares of the biotechnology company’s stock valued at $39,215,000 after acquiring an additional 1,623,851 shares in the last quarter. Temasek Holdings Private Ltd raised its stake in shares of Coherus Biosciences by 12.6% in the fourth quarter. Temasek Holdings Private Ltd now owns 7,381,116 shares of the biotechnology company’s stock worth $132,897,000 after acquiring an additional 825,000 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Coherus Biosciences by 19.3% in the first quarter. JPMorgan Chase & Co. now owns 4,124,245 shares of the biotechnology company’s stock worth $66,896,000 after acquiring an additional 666,775 shares during the last quarter. Hawk Ridge Capital Management LP acquired a new position in Coherus Biosciences during the fourth quarter valued at approximately $11,821,000. Finally, Invesco Ltd. grew its holdings in Coherus Biosciences by 206.8% during the first quarter. Invesco Ltd. now owns 903,522 shares of the biotechnology company’s stock valued at $14,654,000 after purchasing an additional 608,983 shares during the period.
About Coherus Biosciences
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.